Research Solutions Reports Fiscal Third Quarter 2025 Results
Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow
HENDERSON, Nev., May 8, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading AI-powered research workflow platform, reported financial results for its fiscal third quarter ended March 31, 2025.
Fiscal Third Quarter 2025 Summary
- Total revenue of $12.7 million, compared to $12.1 million in the prior-year quarter.
- Platform revenue up 22% to $4.8 million. Platform revenue accounted for 38% of total revenue as compared to 33% in the prior-year quarter.
- Annual Recurring Revenue ("ARR") up 23% to $20.4 million, which includes approximately $13.5 million of B2B recurring revenue and $6.9 million of B2C recurring revenue. Net B2B ARR growth in the quarter was $736,000, a Company record for quarterly B2B growth.
- Gross profit up 14% from the prior-year quarter. Total gross margin improved 430 basis points to 49.5%.
- Net income of $216,000 or $0.01 per diluted share, compared to net income of $76,000 or nil per diluted share in the prior-year quarter.
- Adjusted EBITDA of $1.4 million compared to $961,000 in the prior-year quarter. On a trailing twelve-months ("TTM") basis, the Company has now generated Adjusted EBITDA of $5.1 million, which represents a 10.4% margin.
- Cash flow from operations of approximately $2.9 million in the quarter, which was a Company quarterly record, compared to $2.0 million in the prior-year quarter.
"This quarter represents a number of significant milestone achievements for our Company. We are pleased to report ARR above $20 million for the first time in our history. Revenue from our AI-based B2B offerings has grown over 180% in the last year, and we continue to experience strong growth in our B2C offerings and core Article Galaxy platform. These results are due in part to our revamped sales strategy, which better demonstrates to potential customers the improved efficiency and cost savings offered by our products within the research process workflow," said Roy W. Olivier, President and CEO of Research Solutions. "As we experience strong organic growth in ARR sales, we continue to outperform when it comes to generating operating cash flow and Adjusted EBITDA, which positions us to reinvest in our business or make acquisitions that broaden our product capabilities and enhance our cross-selling opportunities."
Fiscal Third Quarter 2025 Results
Total revenue was $12.7 million, a 4.5% increase from $12.1 million in the year-ago quarter as platform revenue growth more than offset a decline in transaction revenue from the prior period.
Platform subscription revenue increased 22% to $4.8 million compared to $4.0 million in the year-ago quarter. The increase was primarily due to an increase in the total number of paid Platform deployments and B2C subscribers, as well as upsells to existing customers. The quarter ended with annual recurring revenue of $20.4 million, up 23% year-over-year (see the Company's definition of annual recurring revenue below).
Transaction revenue was $7.8 million, compared to $8.2 million in the third quarter of fiscal 2024. The decrease was primarily due to lower paid order volume in the period. The transaction customer count for the quarter was 1,380, compared to 1,426 customers in the prior-year quarter (see the Company's definition of active customer accounts and transactions below).
Total gross margin improved 430 basis points from the prior-year quarter to 49.5%. The increase was primarily driven by a continued revenue mix shift to the higher-margin Platforms business as well as increased margins in that business and the transaction business.
Total operating expenses were $5.7 million, compared to $5.4 million in the third quarter of 2024. The increases were related to additional costs in Sales and Marketing, offset by some reductions in General and Administrative expenses.
Net income for the third quarter was $216,000, or $0.01 per diluted share, compared to net income of $76,000, or nil per diluted share, in the prior-year quarter. Adjusted EBITDA was $1.4 million, compared to $961,000 in the year-ago quarter (see definition and further discussion about the presentation of Adjusted EBITDA, a non-GAAP term, below).
Conference Call
Research Solutions President and CEO Roy W. Olivier and CFO Bill Nurthen will host the conference call, followed by a question and answer period.
Date: Thursday, May 8, 2025
Time: 5:00 p.m. ET (2:00 p.m. PT)
Dial-in number: 1-203-518-9843
Conference ID: RESEARCH
The conference call will be broadcast live and available for replay until June 8, 2025 by dialing 1-412-317-6671 and using the replay ID 11158769, and via the investor relations section of the company's website at http://researchsolutions.investorroom.com/.
Fiscal Third Quarter Financial and Operational Summary Tables vs. Prior-Year Quarter
Quarter Ended March 31, | Nine Months Ended March 31, | |||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||
Revenue: | ||||||||||
Platforms | $ 4,839,929 | $ 3,953,403 | $ 886,526 | 22.4 % | $ 13,770,831 | $ 9,679,179 | $ 4,091,652 | 42.3 % | ||
Transactions | $ 7,821,434 | $ 8,162,269 | (340,835) | -4.2 % | $ 22,849,233 | $ 22,811,206 | 38,027 | 0.2 % | ||
Total Revenue | 12,661,363 | 12,115,672 | 545,691 | 4.5 % | 36,620,064 | 32,490,385 | 4,129,679 | 12.7 % | ||
Gross Profit: | ||||||||||
Platforms | 4,229,623 | 3,382,051 | 847,572 | 25.1 % | 11,993,516 | 8,239,028 | 3,754,488 | 45.6 % | ||
Transactions | 2,037,457 | 2,099,881 | (62,424) | -3.0 % | 5,860,533 | 5,758,272 | 102,261 | 1.8 % | ||
Total Gross Profit | 6,267,080 | 5,481,932 | 785,148 | 14.3 % | 17,854,049 | 13,997,300 | 3,856,749 | 27.6 % | ||
Gross profit as a % of revenue: | ||||||||||
Platforms | 87.4 % | 85.5 % | 1.8 % | 87.1 % | 85.1 % | 2.0 % | ||||
Transactions | 26.0 % | 25.7 % | 0.3 % | 25.6 % | 25.2 % | 0.4 % | ||||
Total Gross Profit | 49.5 % | 45.2 % | 4.3 % | 48.8 % | 43.1 % | 5.7 % | ||||
Operating Expenses: | ||||||||||
Sales and marketing | 1,607,678 | 1,122,365 | 485,313 | 43.2 % | 4,141,172 | 2,612,308 | 1,528,864 | 58.5 % | ||
Technology and product development | 1,394,936 | 1,371,754 | 23,182 | 1.7 % | 4,274,543 | 3,952,891 | 321,652 | 8.1 % | ||
General and administrative | 1,845,411 | 2,027,074 | (181,663) | -9.0 % | 5,783,788 | 6,593,791 | (810,002) | -12.3 % | ||
Depreciation and amortization | 312,013 | 309,898 | 2,115 | 0.7 % | 930,341 | 525,267 | 405,074 | 77.1 % | ||
Stock-based compensation | 594,639 | 541,002 | 53,637 | 9.9 % | 1,546,950 | 1,729,271 | (182,321) | -10.5 % | ||
Foreign currency translation loss | (44,519) | 22,177 | (66,696) | NM | (119,205) | 15,059 | (134,264) | NM | ||
Total Operating Expenses | 5,710,158 | 5,394,270 | 315,888 | 5.9 % | 16,557,589 | 15,428,587 | 1,129,003 | 7.3 % | ||
Income (loss) from operations | 556,922 | 87,663 | 469,259 | 535.3 % | 1,296,460 | (1,431,286) | 2,727,746 | NM | ||
Other Income (Expenses): | ||||||||||
Other income | (327,042) | 31,228 | (358,270) | NM | (2,316,404) | 547,965 | (2,864,369) | NM | ||
Provision for income taxes | (13,410) | (42,590) | 29,180 | -68.5 % | (74,816) | (82,049) | 7,233 | -8.8 % | ||
Total Other Income (Expenses): | (340,452) | (11,362) | (329,090) | NM | (2,391,220) | 465,916 | (2,857,136) | NM | ||
Net income (loss) | $ 216,470 | $ 76,301 | 140,169 | 183.7 % | $ (1,094,760) | $ (965,370) | (129,390) | -13.4 % | ||
NM | ||||||||||
Adjusted EBITDA | $ 1,419,055 | $ 960,740 | $ 458,315 | 47.7 % | $ 3,654,546 | $ 838,311 | $ 2,816,235 | 335.9 % | ||
Quarter Ended March 31, | Nine Months Ended March 31, | |||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||
Platforms: | ||||||||||
B2B ARR (Annual recurring revenue*): | ||||||||||
Beginning of Period | $ 12,738,256 | $ 11,614,748 | $ 1,123,508 | 9.7 % | $ 12,060,201 | $ 9,444,130 | $ 2,616,071 | 27.7 % | ||
Incremental ARR | 735,818 | 38,315 | 697,503 | 1820.4 % | 1,413,873 | 2,208,933 | (795,060) | -36.0 % | ||
End of Period | $ 13,474,074 | $ 11,653,063 | $ 1,821,011 | 15.6 % | $ 13,474,074 | $ 11,653,063 | $ 1,821,012 | 15.6 % | ||
Deployments: | ||||||||||
Beginning of Period | 1,090 | 942 | 148 | 15.7 % | 1,021 | 835 | 186 | 22.3 % | ||
Incremental Deployments | 43 | 41 | 2 | 4.9 % | 112 | 148 | (36) | -24.3 % | ||
End of Period | 1,133 | 983 | 150 | 15.3 % | 1,133 | 983 | 150 | 15.3 % | ||
ASP (Average sales price): | ||||||||||
Beginning of Period | $ 11,686 | $ 12,330 | $ (643) | -5.2 % | $ 11,812 | $ 11,310 | $ 502 | 4.4 % | ||
End of Period | $ 11,892 | $ 11,855 | $ 38 | 0.3 % | $ 11,892 | $ 11,855 | $ 38 | 0.3 % | ||
B2C ARR (Annual recurring revenue*): | ||||||||||
Beginning of Period | $ 6,371,381 | $ 3,954,090 | $ 2,417,291 | 61.1 % | $ 5,363,129 | $ - | $ 5,363,129 | NM | ||
Incremental ARR | 506,545 | 948,885 | (442,340) | NM | 1,514,797 | 4,902,975 | (3,388,178) | NM | ||
End of Period | $ 6,877,926 | $ 4,902,975 | $ 1,974,951 | 40.3 % | $ 6,877,926 | $ 4,902,975 | $ 1,974,951 | 40.3 % | ||
Total ARR (Annualized recurring revenue): | $ 20,352,000 | $ 16,556,038 | $ 3,795,962 | 22.9 % | $ 20,352,000 | $ 16,556,038 | $ 3,795,963 | 22.9 % | ||
Transaction Customers: | ||||||||||
Corporate customers | 1,060 | 1,105 | (45) | -4.1 % | 1,062 | 1,087 | (25) | -2.3 % | ||
Academic customers | 320 | 321 | (1) | -0.3 % | 323 | 320 | 3 | 1.0 % | ||
Total customers | 1,380 | 1,426 | (46) | -3.2 % | 1,385 | 1,407 | (22) | -1.5 % | ||
Active Customer Accounts, Transactions and Annual Recurring Revenue
The Company defines active customer accounts as the sum of the total quantity of customers per month for each month in the period divided by the respective number of months in the period. The quantity of customers per month is defined as customers with at least one transaction during the month.
A transaction is an order for a unit of copyrighted content fulfilled or managed in the Platform.
The Company defines annual recurring revenue ("ARR") as the value of contracted Platform subscription recurring revenue normalized to a one-year period. For B2C ARR, this includes the annualized value of monthly subscriptions, meaning their monthly value multiplied by twelve.
Use of Non-GAAP Measure – Adjusted EBITDA
Research Solutions' management evaluates and makes operating decisions using various financial metrics. In addition to the Company's GAAP results, management also considers the non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP measure provides useful information about the Company's operating results.
The tables below provide a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure. Adjusted EBITDA is defined as net income (loss), plus interest expense, other income (expense) including any change in fair value of contingent earnout liability, foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, and other potential adjustments that may arise. Set forth below is a reconciliation of Adjusted EBITDA to net income (loss):
Quarter Ended March 31, | Nine Months Ended March 31, | ||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | ||
Net Income (loss) | $ 216,470 | $ 76,301 | $ 140,169 | 183.7 % | $ (1,094,760) | $ (965,370) | $ (129,390) | -13.4 % | |
Add (deduct): | - | ||||||||
Other (income) expense | 327,042 | (31,228) | 358,270 | NM | 2,316,404 | (547,965) | 2,864,369 | NM | |
Foreign currency translation loss (gain) | (44,519) | 22,177 | (66,696) | NM | (119,205) | 15,059 | (134,264) | NM | |
Provision for income taxes | 13,410 | 42,590 | (29,180) | -68.5 % | 74,816 | 82,049 | (7,233) | -8.8 % | |
Depreciation and amortization | 312,013 | 309,898 | 2,115 | 0.7 % | 930,341 | 525,267 | 405,074 | 77.1 % | |
Stock-based compensation | 594,639 | 541,002 | 53,637 | 9.9 % | 1,546,950 | 1,729,271 | (182,321) | -10.5 % | |
Adjusted EBITDA | $ 1,419,055 | $ 960,740 | $ 458,315 | 47.7 % | $ 3,654,546 | $ 838,311 | $ 2,816,235 | 335.9 % | |
About Research Solutions
Research Solutions, Inc. (NASDAQ: RSSS) provides cloud-based technologies to streamline the process of obtaining, managing, and creating intellectual property. Founded in 2006 as Reprints Desk, the Company was a pioneer in developing solutions to serve researchers. Today, more than 70 percent of the top pharmaceutical companies, prestigious universities, and emerging businesses rely on Article Galaxy, the Company's SaaS research platform, to streamline access to the latest scientific research and data with 24/7 customer support. For more information and details, please visit www.researchsolutions.com
Important Cautions Regarding Forward-Looking Statements
Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company's most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Examples of forward-looking statements in this release include statements regarding enhanced product offerings, additional customers, and the Company's prospects for growth. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company's filings with the Securities and Exchange Commission.
Research Solutions, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) | |||||||
March 31, | June 30, | ||||||
2025 | 2024 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 9,852,007 | $ | 6,100,031 | |||
Accounts receivable, net of allowance of $82,026 and $68,579, respectively | 7,604,058 | 6,879,800 | |||||
Prepaid expenses and other current assets | 625,727 | 643,553 | |||||
Prepaid royalties | 755,299 | 1,067,237 | |||||
Total current assets | 18,837,091 | 14,690,621 | |||||
Non-current assets: | |||||||
Property and equipment, net of accumulated depreciation of $944,694 and $922,558, respectively | 60,051 | 88,011 | |||||
Intangible assets, net of accumulated amortization of $2,431,738 and $1,535,310, respectively | 9,956,378 | 10,764,261 | |||||
Goodwill | 16,372,979 | 16,315,888 | |||||
Deposits and other assets | 881 | 981 | |||||
Total assets | $ | 45,227,380 | $ | 41,859,762 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable and accrued expenses | $ | 8,529,572 | $ | 8,843,612 | |||
Deferred revenue | 10,355,768 | 9,023,848 | |||||
Contingent earnout liability, current portion | 6,019,488 | — | |||||
Total current liabilities | 24,904,828 | 17,867,460 | |||||
Non-current liabilities: | |||||||
Contingent earnout liability, long-term portion | 9,091,422 | 12,298,114 | |||||
Total liabilities | 33,996,250 | 30,165,574 | |||||
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding | — | — | |||||
Common stock; $0.001 par value; 100,000,000 shares authorized; 32,405,120 and 32,295,373 shares | 32,405 | 32,295 | |||||
Additional paid-in capital | 38,728,405 | 38,089,958 | |||||
Accumulated deficit | (27,404,006) | (26,309,246) | |||||
Accumulated other comprehensive loss | (125,674) | (118,819) | |||||
Total stockholders' equity | 11,231,130 | 11,694,188 | |||||
Total liabilities and stockholders' equity | $ | 45,227,380 | $ | 41,859,762 | |||
Research Solutions, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) | |||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||
March 31, | March 31, | ||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||
Revenue: | |||||||||||||
Platforms | $ | 4,839,929 | $ | 3,953,403 | $ | 13,770,831 | $ | 9,679,179 | |||||
Transactions | 7,821,434 | 8,162,269 | 22,849,233 | 22,811,206 | |||||||||
Total revenue | 12,661,363 | 12,115,672 | 36,620,064 | 32,490,385 | |||||||||
Cost of revenue: | |||||||||||||
Platforms | 610,306 | 571,352 | 1,777,315 | 1,440,151 | |||||||||
Transactions | 5,783,977 | 6,062,388 | 16,988,700 | 17,052,934 | |||||||||
Total cost of revenue | 6,394,283 | 6,633,740 | 18,766,015 | 18,493,085 | |||||||||
Gross profit | 6,267,080 | 5,481,932 | 17,854,049 | 13,997,300 | |||||||||
Operating expenses: | |||||||||||||
Selling, general and administrative | 5,398,145 | 5,084,371 | 15,627,248 | 14,903,319 | |||||||||
Depreciation and amortization | 312,013 | 309,898 | 930,341 | 525,267 | |||||||||
Total operating expenses | 5,710,158 | 5,394,269 | 16,557,589 | 15,428,586 | |||||||||
Income (loss) from operations | 556,922 | 87,663 | 1,296,460 | (1,431,286) | |||||||||
Other income | 78,868 | 31,228 | 496,392 | 279,678 | |||||||||
Change in fair value of contingent earnout liability | (405,910) | — | (2,812,796) | 268,287 | |||||||||
Income (loss) before provision for income taxes | 229,880 | 118,891 | (1,019,944) | (883,321) | |||||||||
Provision for income taxes | (13,410) | (42,590) | (74,816) | (82,049) | |||||||||
Net income (loss) | 216,470 | 76,301 | (1,094,760) | (965,370) | |||||||||
Other comprehensive income (loss): | |||||||||||||
Foreign currency translation | (3,324) | 858 | (6,855) | 6,261 | |||||||||
Comprehensive income (loss) | $ | 213,146 | $ | 77,159 | $ | (1,101,615) | $ | (959,109) | |||||
Basic income (loss) per common share: | |||||||||||||
Net income (loss) per share | $ | 0.01 | $ | - | $ | (0.04) | $ | (0.03) | |||||
Weighted average common shares outstanding | 31,033,022 | 30,020,652 | 30,597,410 | 28,377,199 | |||||||||
Diluted income (loss) per common share: | |||||||||||||
Net income (loss) per share | $ | 0.01 | $ | - | $ | (0.04) | $ | (0.03) | |||||
Weighted average common shares outstanding | 32,139,935 | 33,511,242 | 30,597,410 | 28,377,199 | |||||||||
Research Solutions, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
Nine Months Ended | |||||||
March 31, | |||||||
2025 | 2024 | ||||||
Cash flow from operating activities: | |||||||
Net loss | $ | (1,094,760) | $ | (965,370) | |||
Adjustment to reconcile net loss to net cash provided by operating activities: | |||||||
Depreciation and amortization | 930,341 | 525,267 | |||||
Stock options expense | 146,751 | 104,502 | |||||
Restricted common stock expense | 1,400,199 | 1,603,820 | |||||
Modification cost of accelerated vesting of restricted common stock | — | 20,949 | |||||
Adjustment to contingent earnout liability | 2,812,796 | (268,287) | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | (754,258) | (739,883) | |||||
Prepaid expenses and other current assets | 17,826 | (156,026) | |||||
Prepaid royalties | 311,938 | 197,888 | |||||
Accounts payable and accrued expenses | (338,502) | 498,584 | |||||
Deferred revenue | 1,331,920 | 768,347 | |||||
Net cash provided by operating activities | 4,764,251 | 1,589,791 | |||||
Cash flow from investing activities: | |||||||
Purchase of property and equipment | (11,571) | (57,761) | |||||
Payment for acquisition of Resolute, net of cash acquired | — | (2,718,253) | |||||
Payment for acquisition of Scite, net of cash acquired | — | (7,305,493) | |||||
Net cash used in investing activities | (11,571) | (10,081,507) | |||||
Cash flow from financing activities: | |||||||
Common stock repurchase | (908,393) | (522,024) | |||||
Payment of contingent acquisition consideration | (91,174) | (314,960) | |||||
Net cash used in financing activities | (999,567) | (836,984) | |||||
Effect of exchange rate changes | (1,137) | 4,791 | |||||
Net increase (decrease) in cash and cash equivalents | 3,751,976 | (9,323,909) | |||||
Cash and cash equivalents, beginning of period | 6,100,031 | 13,545,333 | |||||
Cash and cash equivalents, end of period | $ | 9,852,007 | $ | 4,221,424 | |||
Supplemental disclosures of cash flow information: | |||||||
Cash paid for income taxes | $ | 74,816 | $ | 82,049 | |||
Non-cash investing and financing activities: | |||||||
Contingent consideration accrual on asset acquisition | $ | 29,394 | $ | 36,130 | |||
SOURCE Research Solutions, Inc.
Share this article